S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
pixel
pixel
pixel

MassMutual fined for failing to monitor GameStop saga star

Thursday, September 16, 2021 | The Associated Press


In this image from video provided by the House Financial Services Committee, Keith Gill, also known in social media forums as Roaring Kitty, testifies during a virtual hearing on GameStop in Washington, Thursday, Feb. 18, 2021. Massachusetts is fining MassMutual $4 million and ordering it to overhaul its social-media policies after accusing the company of failing to supervise the employee whose online cheerleading of GameStop’s stock helped launch the frenzy that shook Wall Street earlier this year. The settlement announced Thursday, Sept. 16, 2021 centers on the actions of Gill, an employee at a MassMutual subsidiary from April 2019 until January 2021. (House Financial Services Committee via AP)

NEW YORK (AP) — Massachusetts regulators are fining MassMutual $4 million and ordering it to overhaul its social-media policies after accusing the company of failing to supervise an employee whose online cheerleading of GameStop's stock helped launch the frenzy that shook Wall Street earlier this year.

The settlement announced Thursday by Secretary of the Commonwealth William Galvin centers on the actions of Keith Gill, who was an employee at a MassMutual subsidiary from April 2019 until January 2021. His tenure ended as GameStop's stock price suddenly soared nearly 800% in a week, as hordes of smaller-pocketed and novice investors piled in, to the shock and awe of professionals.

Gill's job at MassMutual was to create educational materials for current and potential customers, but regulators say he was also posting more than 250 hours of videos on YouTube and sending at least 590 Tweets about investing and GameStop through accounts that were unaffiliated with the company.

Massachusetts regulators cited those messages while alleging MassMutual failed to monitor the social-media accounts of Gill and other employees who were registered as broker-dealer agents in the state, and therefore subject to certain supervision requirements. The MassMutual unit where Gill worked prohibits broker-dealer agents from discussing generic securities on social media.

In his online messages, Gill would often talk about why he owned and was optimistic about GameStop’s stock, even though it had been struggling for years. He used the nicknames “Roaring Kitty” and “DeepValue,” with an expletive in the middle of the latter one, and he amassed tens of thousands of followers. He also posted regular updates on Reddit about his GameStop holdings, which ballooned into the tens of millions of dollars.

Gill, and the red headband he wore in many of his videos, became such central characters in the GameStop phenomenon that he testified in a Congressional hearing about it. There he professed once again, “I like the stock,” a statement that became a rallying cry for GameStop investors in forums across the internet. GameStop shares started the year at around $19 and closed Thursday at $206.37.

Regulators also said MassMutual failed to have reasonable policies and procedures to monitor the personal trading of its registered agents, among other things. To watch for excessive trading, for example, the MassMutual unit where Gill worked had a rule to flag transactions of $250,000 or more in a single security made across all the accounts by registered representatives. Regulators say Gill sold $750,000 worth of GameStop options and bought $703,600 of GameStop stock in one day during January, but his employer’s trade surveillance system didn’t flag either of the trades.

In the settlement, MassMutual neither admitted nor denied state regulators' findings. It said in a statement that it's “pleased to put this matter behind us, avoiding the expense and distraction associated with protracted litigation.”


7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022

One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.

But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.

There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.

However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that are ready to make strong moves forward in 2022.

View the "7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022".


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.